People: Zogenix Inc (ZGNX.O)

ZGNX.O on Consolidated Issue listed on NASDAQ Global Market

9.79USD
12 Feb 2016
Change (% chg)

$0.27 (+2.84%)
Prev Close
$9.52
Open
$9.71
Day's High
$9.85
Day's Low
$9.13
Volume
390,413
Avg. Vol
372,824
52-wk High
$21.65
52-wk Low
$7.90

Search Stocks

Farr, Stephen 

Dr. Stephen J. Farr, Ph.D., has been appointed as President, Chief Executive Officer, Director of the Company. Stephen J. Farr, Ph.D., is one of our co-founders and has served as our President and as a member of our board of directors since our inception in May 2006. Beginning in April 2015, Dr. Farr is also serving as our Chief Executive Officer. From May 2006 to August 2006, Dr. Farr also served as our Chief Executive Officer and from August 2006 to March 2013, Dr. Farr also served as our Chief Operating Officer. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. in Pharmaceutics from the University of Wales. As one of our co-founders and having served as our President since May 2006, Dr. Farr’s extensive knowledge of our business, history and culture, as well as his significant experience in research and development and thorough knowledge of the pharmaceutical product development process, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 604,794
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 773,325
Fiscal Year Total, USD 1,378,120

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Search Stocks